Laws, H., Fukutake, K., López Fernández, M. F., Li, Y., Seifert, W., & Tagliaferri, A. (2023). Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ?2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.

Laws, H.-J., K. Fukutake, María Fernanda López Fernández, Y. Li, W. Seifert, and A. Tagliaferri. Assessment of Joint Bleeding and Target Joints in Patients With Severe or Moderately Severe Hemophilia B (factor IX ?2%) Receiving Prophylaxis With RIX-FP in the PROLONG-9FP Clinical Trial Program. 2023.

Laws, H.-J., et al. Assessment of Joint Bleeding and Target Joints in Patients With Severe or Moderately Severe Hemophilia B (factor IX ?2%) Receiving Prophylaxis With RIX-FP in the PROLONG-9FP Clinical Trial Program. 2023.